Carpal Tunnel Syndrome better with palmitoylethanolamide

Carpal Tunnel Syndrome better with palmitoylethanolamide

The pain and distress on the nerves with carpal tunnel syndrome decrease after treatment with the bodily pain relieving and anti-inflammatory substance palmitoylethanolamide (PEA).


Less complaints and improved nerve transmission in carpal tunnel syndrome due to PEA.

Both the subjective complaints as well as the objective measurable speed with which the nerve impulses are transmitted through the nerves, have improved significantly by treatment with PEA supplement compared to the placebo. [1]

First we discuss the improvement of the transmission through the nerves in the wrist. With carpal tunnel syndrome, the nerves are pinched. This causes pain and numbness in the hand, which sometimes makes it hard to hold small objects with the fingers. These are all signs that the nerve is struggling.

Prior to this study there was no method to support the nerves, other than the surgeon’s knife. The neurosurgeon can perform surgery to treat carpal tunnel syndrome. In this case, the surgeon opens the hand at the wrist and creates more space for the nerve.

Now we can do the same with a supplement from the inside out. PEA helps to release pressure inside of the nerve, so the chronic inflammation of the nerve decreases and through this simultaneously decreases the pain. In the picture above you can see that 600mg per day already shows a clear measurable effect on the impulses that go through the nerve. But with a dose of 1200mg daily this effect is even more significant.


Subjective complaints of carpal tunnel syndrome also decrease significantly with PEA

The researchers also surveyed the subjective complaints of the patients. Here we saw the same pattern: 300mg PEA twice a day decreased the complaints slightly, but 600mg was significantly more effective, also compared to the placebo. The results can be seen in the table. Both doses of PEA did better than the placebo, and the highest doses had the most effect.

These results are completely identical to a large study on over 600 patients with severe hernia pain. That was also a placebo-controlled study in which both doses did better than the placebo and 600mg twice a day was the most effective dose.

In 2011 the positive effects of palmitoylethanolamide were not only proven in clinical studies like this one with carpal tunnel syndrome, but the effects were also remarkably positive in studies about the effects on models with severe spinal damage. [2] In another model for dementia (Alzheimer) palmitoylethanolamide also showed to significantly counteract the brain damage in Alzheimer’ disease. [3] And in models for nasty chronic inflammation responded positively to palmitoylethanolamide. [4]


PEA: Nerve protection, anti-inflammatory and pain relief

This makes the body’s own pain relieving, anti-inflammatory substance palmitoylethanolamide one of the most studied supplements. Time in time again, the positive effects were confirmed and the substance seems to be perfect for treating chronic pain, even more so because there are practically no side effects. The effects have been measured in several studies and come down to nerve protection, anti-inflammatory and pain relief.

We give a green light for PEA concerning the treatment of nerve conditions like carpal tunnel syndrome, pain due to diabetes and severe hernia.

Main reference:

Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist.Minerva Med. 2011 Apr;102(2):141-7.


[1] Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V.  (2011 Apr). Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med. Apr

[2] Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. ( 2011 Feb 25). Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun.

[3] Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. (2011 Dec). Palmitoylethanolamide counteracts reactive astrogliosis induced by ?-amyloid peptide. J Cell Mol Med.

[4] De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T. (2011 Jan 10). Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain.